Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Charles E. Rupprecht is active.

Publication


Featured researches published by Charles E. Rupprecht.


Proceedings of the Royal Society of London B: Biological Sciences | 2013

A comparison of bats and rodents as reservoirs of zoonotic viruses: are bats special?

Angela D. Luis; David T. S. Hayman; Thomas J. O'Shea; Paul M. Cryan; Amy T. Gilbert; Juliet R. C. Pulliam; James N. Mills; Mary E. Timonin; Craig K. R. Willis; Andrew A. Cunningham; Anthony R. Fooks; Charles E. Rupprecht; J. L. N. Wood; Colleen T. Webb

Bats are the natural reservoirs of a number of high-impact viral zoonoses. We present a quantitative analysis to address the hypothesis that bats are unique in their propensity to host zoonotic viruses based on a comparison with rodents, another important host order. We found that bats indeed host more zoonotic viruses per species than rodents, and we identified life-history and ecological factors that promote zoonotic viral richness. More zoonotic viruses are hosted by species whose distributions overlap with a greater number of other species in the same taxonomic order (sympatry). Specifically in bats, there was evidence for increased zoonotic viral richness in species with smaller litters (one young), greater longevity and more litters per year. Furthermore, our results point to a new hypothesis to explain in part why bats host more zoonotic viruses per species: the stronger effect of sympatry in bats and more viruses shared between bat species suggests that interspecific transmission is more prevalent among bats than among rodents. Although bats host more zoonotic viruses per species, the total number of zoonotic viruses identified in bats (61) was lower than in rodents (68), a result of there being approximately twice the number of rodent species as bat species. Therefore, rodents should still be a serious concern as reservoirs of emerging viruses. These findings shed light on disease emergence and perpetuation mechanisms and may help lead to a predictive framework for identifying future emerging infectious virus reservoirs.


Clinical Infectious Diseases | 2013

Case Definitions, Diagnostic Algorithms, and Priorities in Encephalitis: Consensus Statement of the International Encephalitis Consortium

Arun Venkatesan; Allan R. Tunkel; Karen C. Bloch; Adam S. Lauring; James J. Sejvar; Ari Bitnun; Jean Paul Stahl; A. Mailles; M. Drebot; Charles E. Rupprecht; Jonathan S. Yoder; Jennifer R. Cope; Michael R. Wilson; Richard J. Whitley; John S. Sullivan; Julia Granerod; Cheryl A. Jones; Keith Eastwood; Katherine N. Ward; David N. Durrheim; M. V. Solbrig; L. Guo-Dong; Carol A. Glaser; Heather Sheriff; David W. Brown; Eileen C. Farnon; Sharon Messenger; Beverley J. Paterson; Ariane Soldatos; Sharon L. Roy

BACKGROUND Encephalitis continues to result in substantial morbidity and mortality worldwide. Advances in diagnosis and management have been limited, in part, by a lack of consensus on case definitions, standardized diagnostic approaches, and priorities for research. METHODS In March 2012, the International Encephalitis Consortium, a committee begun in 2010 with members worldwide, held a meeting in Atlanta to discuss recent advances in encephalitis and to set priorities for future study. RESULTS We present a consensus document that proposes a standardized case definition and diagnostic guidelines for evaluation of adults and children with suspected encephalitis. In addition, areas of research priority, including host genetics and selected emerging infections, are discussed. CONCLUSIONS We anticipate that this document, representing a synthesis of our discussions and supported by literature, will serve as a practical aid to clinicians evaluating patients with suspected encephalitis and will identify key areas and approaches to advance our knowledge of encephalitis.


Annals of Neurology | 2014

Phylogenetic and epidemiologic evidence of multiyear incubation in human rabies

Torrey Boland; Declan McGuone; Jenelle Jindal; Marcelo Rocha; Melissa Cumming; Charles E. Rupprecht; Taciana Fernandes Souza Barbosa; Rafael de Novaes Oliveira; Catherine J. Chu; Andrew J. Cole; Ivanete Kotait; Natalia Kuzmina; Pamela A. Yager; Ivan V. Kuzmin; E. Tessa Hedley-Whyte; Catherine M. Brown; Eric Rosenthal

Eight years after emigrating from Brazil, an otherwise healthy man developed rabies. An exposure prior to immigration was reported. Genetic analysis revealed a canine rabies virus variant found only in the patients home country, and the patient had not traveled internationally since immigrating to the United States. We describe how epidemiological, phylogenetic, and viral sequencing data provided confirmation that rabies encephalomyelitis may present after a long, multiyear incubation period, a consideration that previously has been hypothesized without the ability to exclude a more recent exposure. Accordingly, rabies should be considered in the diagnosis of any acute encephalitis, myelitis, or encephalomyelitis. ANN NEUROL 2014;75:155–160


Vaccine | 2013

Concomitant administration of GonaCon™ and rabies vaccine in female dogs (Canis familiaris) in Mexico.

Fernando Vargas-Pino; Verónica Gutiérrez-Cedillo; Erick J. Canales-Vargas; Luis R. Gress-Ortega; Lowell A. Miller; Charles E. Rupprecht; Scott C. Bender; Patricia García-Reyna; Juan Ocampo-López; Dennis Slate

Mexico serves as a global model for advances in rabies prevention and control in dogs. The Mexican Ministry of Health (MMH) annual application of approximately 16 million doses of parenteral rabies vaccine has resulted in significant reductions in canine rabies during the past 20 years. One collateral parameter of rabies programs is dog population management. Enhanced public awareness is critical to reinforce responsible pet ownership. Surgical spaying and neutering remain important to prevent reproduction, but are impractical for achieving dog population management goals. GonaCon™, an anti-gonadotropin releasing hormone (GnRH) vaccine, was initially tested in captive female dogs on the Navajo Nation, 2008. The MMH led this international collaborative study on an improved formulation of GonaCon™ in captive dogs with local representatives in Hidalgo, Mexico in 2011. This study contained 20 bitches assigned to Group A (6 control), Group B (7 GonaCon™), and Group C (7 GonaCon™ and rabies vaccine). Vaccines were delivered IM. Animals were placed under observation and evaluated during the 61-day trial. Clinically, all dogs behaved normally. No limping or prostration was observed, in spite of minor muscle atrophy post-mortem in the left hind leg of dogs that received GonaCon™. Two dogs that began the study pregnant give birth to healthy pups. Dogs that received a GonaCon™ injection had macro and microscopic lesions consistent with prior findings, but the adverse injection effects were less frequent and lower in intensity. Both vaccines were immunogenic based on significant increases in rabies virus neutralizing antibodies and anti-GnRH antibodies in treatment Groups B and C. Simultaneous administration of GonaCon™ and rabies vaccine in Group C did not affect immunogenicity. Progesterone was suppressed significantly in comparison to controls. Future studies that monitor fertility through multiple breeding cycles represent a research need to determine the value of integrating this vaccine into dog rabies management.


Rabies (Third Edition)#R##N#Scientific Basis of the Disease and Its Management | 2013

Chapter 13 – Rabies Vaccines

Deborah J. Briggs; Thirumeni Nagarajan; Charles E. Rupprecht

Rabies vaccine is the most valuable tool to prevent rabies in humans and animals. Vaccines provide the best service to public health when used in concert with effective risk management assessment systems that include enhanced surveillance, reliable de-centralized diagnostic laboratories and continued education for health professionals. All modern human rabies vaccines are inactivated, but both inactivated and modified-live or recombinant rabies cell culture rabies vaccines are produced for use in animals.


Zoonoses - Infections Affecting Humans and Animals : Focus on Public Health Aspects | 2015

Elimination of Rabies—A Missed Opportunity

Thomas Müller; Conrad Martin Freuling; Charles E. Rupprecht; Leonard Both; Anthony R. Fooks; Tiziana Lembo; Lea Knopf; Deborah J. Briggs; Louise H. Taylor

Rabies is one of the oldest known zoonoses. Recognized etiological agents consist of at least 15 proposed species of lyssaviruses with primary reservoirs residing in the Orders Carnivora and Chiroptera. A plethora of viral variants, maintained by a diverse set of abundant hosts, presents a formidable challenge to a strict concept of true disease eradication. Despite the availability of affordable and efficacious animal and human vaccines, today however dog rabies continues to escalate unabated across much of Asia and Africa, causing millions of suspect human exposures and tens of thousands of human rabies deaths annually. By identifying what hampers global human rabies elimination this chapter emphasizes that, given the global epidemiology of rabies, the “One Health” concept is key to solving the problem. Next to state of the art human rabies prevention, immunization and experimental therapy, it is obvious that human rabies can only be eliminated through rabies control at the animal source. This ‘paradigm shift’, however, needs new grassroot initiatives as well as political will and the closing of ranks of all stakeholders in the near future.


Antiviral Research | 2013

Current and future tools for global canine rabies elimination

Richard Franka; Todd G. Smith; Jessie L. Dyer; Xianfu Wu; Michael Niezgoda; Charles E. Rupprecht


Journal of Travel Medicine | 2013

The Global Availability of Rabies Immune Globulin and Rabies Vaccine in Clinics Providing Indirect Care to Travelers

Emily S. Jentes; Jesse D. Blanton; Katherine J. Johnson; Brett W. Petersen; Mark J. Lamias; Kis Robertson; Richard Franka; Daniel Muhm; Charles E. Rupprecht; Nina Marano; Gary W. Brunette


Archive | 2002

Oral Rabies Vaccination: A National Perspective on Program Development and Implementation

Dennis Slate; Richard B. Chipman; Charles E. Rupprecht; Thomas J. DeLiberto


Archive | 2011

Human Rabies Epidemiology and Diagnosis

Brett W. Petersen; Charles E. Rupprecht

Collaboration


Dive into the Charles E. Rupprecht's collaboration.

Top Co-Authors

Avatar

Dennis Slate

United States Department of Agriculture

View shared research outputs
Top Co-Authors

Avatar

Richard B. Chipman

United States Department of Agriculture

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Amy T. Gilbert

United States Department of Agriculture

View shared research outputs
Top Co-Authors

Avatar

Michael Niezgoda

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Richard Franka

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Brett W. Petersen

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jesse D. Blanton

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jessie L. Dyer

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge